Healthcare
Synlogic, Inc.(SYBX)
Live Price
Offline$0.71
+0.00% today
1Y Change
-36.75%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $10.00M
- Revenue Growth
- -100.0%
- EPS Growth
- +95.8%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Synlogic, Inc. (SYBX) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $0.71 and down 36.8% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +95.8%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +95.8%, free cash flow +86.2% with operating margin 0.0% and ROIC -33.8%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SYBX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at +95.8%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +7.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +7.5% | +6.7% | +16.7% |
2026 Mar 12, 2026 | +233.3% | +1.7% | +19.2% | +4.2% |
2025 Nov 13, 2025 | -72.7% | +0.6% | -4.2% | -33.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYBX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SYBX Max Drawdown
-69.40%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SYBX and SPY.
Company Overview
Synlogic, Inc.
NASDAQ Global Market
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
- Leadership
- Mary Beth Dooley
- IPO Date
- Sep 30, 2015
- Employees
- 1
- Street Address
- 301 Binney Street
- Mailing
- Cambridge, MA, 02142
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 401 9975
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 2.1
- Price/Sales
- โ
- Price/Book
- 0.6
Growth
- Revenue
- -100.0%
- EPS
- +95.8%
- Free Cash Flow
- +86.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -8.4%
- ROIC
- -33.8%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 4.30
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.